# Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

> **NCT05395624** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ashvattha Therapeutics, Inc.** · enrollment: 65 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)
- Parkinson Disease (PD)
- Alzheimer Disease (AD)
- Multiple Sclerosis (MS)

## Interventions

- **DRUG:** 18F-OP-801

## Key facts

- **NCT ID:** NCT05395624
- **Lead sponsor:** Ashvattha Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-02
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05395624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05395624, "Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05395624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*